Driehuis, E., Kolders, S., Spelier, S., Lohmussaar, K., Willems, S. M., Devriese, L. A., de Bree, R., de Ruiter, E. J., Korving, J., Begthel, H., Van Es, J. H., Geurts, V., He, G. W., van Jaarsveld, R. H., Oka, R., Muraro, M. J., Vivie, J., Zandvliet, Mmjm, Hendrickx, A. P. A., Iakobachvili, N., Sridevi, P., Kranenburg, O., van Boxtel, R., Kops, Gjpl, Tuveson, D. A., Peters, P. J., van Oudenaarden, A., Clevers, H. (May 2019) Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov, 9 (7). pp. 852-871. ISSN 2159-8274
Abstract
Previous studies have described that tumor organoids can capture the diversity of defined human carcinoma types. Here, we describe conditions for long-term culture of human mucosal organoids. Using this protocol, a panel of 31 head and neck squamous cell carcinoma (HNSCC)-derived organoid lines was established. This panel recapitulates genetic and molecular characteristics previously described for HNSCC. Organoids retain their tumorigenic potential upon xenotransplantation. We observe differential responses to a panel of drugs including cisplatin, carboplatin, cetuximab and radiotherapy in vitro. Drug screens reveals selective sensitivity to targeted drugs that are not normally used in the treatment of HNSCC patients. These observations may inspire a personalized approach to the management of HNSCC and expand the repertoire of HNSCC drugs.
| Item Type: | Paper |
|---|---|
| Subjects: | Investigative techniques and equipment > cell culture > cancer organoids diseases & disorders > cancer > drugs and therapies therapies > personalised therapy |
| CSHL Authors: | |
| Communities: | CSHL labs > Tuveson lab CSHL Cancer Center Program > Cellular Communication in Cancer Program |
| Depositing User: | Matthew Dunn |
| Date: | 3 May 2019 |
| Date Deposited: | 22 May 2019 15:05 |
| Last Modified: | 26 Oct 2020 15:39 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/37826 |
Actions (login required)
 |
Administrator's edit/view item |
